September 20, 2019 | Joanne Morrison
Dr. Kathleen Neuzil to Lead Major Research Collaborative with Ultimate Goal of Protecting Millions Against Emerging Influenza Strains
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with total funding up to more than $200 million over seven years if all contract options are exercised.
This research contract is one of the largest ever awarded to UMSOM and includes an initial award of approximately $2.5 million to conduct clinical testing of influenza vaccines.
CVD’s research is aimed at testing improved seasonal influenza vaccines and conducting controlled human influenza challenge studies for NIAID's Collaborative Influenza Vaccine Innovation Center (CIVICs) program, which has the ultimate goal of developing a universal vaccine to protect against emerging influenza strains as well as improvements to current seasonal vaccines.
The seven-year contract will be led by CVD’s Dr. Neuzil, who is one of the world’s leading and preeminent research scientists and advocates in the area of vaccine development and policy. For more than four decades, CVD has worked domestically and internationally to develop, test and deploy vaccines to prevent and protect against a range of diseases, such as influenza, cholera, typhoid fever, malaria, shigellosis (bacillary dysentery), and other infectious diseases. CVD has also taken global leadership roles in vaccines to protect against emerging pathogens such as Zika and Ebola virus.
News Conference remarks of Dr. CVD Director Dr. Kathleen Neuzil
The CIVICs program includes multidisciplinary research across a large network of institutions, supporting the development of vaccine candidates through testing in pre-clinical studies, clinical trials and human challenge studies. This new CVD funding will establish a CVD CIVIC Clinical Core, with the specific goal of evaluating improved seasonal influenza vaccines and ultimately developing a universal vaccine to protect against emerging influenza strains.
Influenza, a contagious respiratory illness, is one of the greatest infectious disease threats to health and well-being. The disease impacted 43 million people in the U.S. alone during the 2018-2019 season, according to the Centers for Disease Control and Prevention (CDC). While current vaccines are our best tool to protect against influenza and its complications, the CVD CIVIC will address the urgent need for novel vaccines that provide broad and long-lasting protection.
As Principal Investigator, Dr. Neuzil will serve as the primary liaison with NIH program officers, CIVICs partners and technical centers.
“Influenza virus is a common and serious infection that causes annual outbreaks in all age groups. While current influenza vaccines have been critical in reducing disease, the virus is constantly changing. The CIVICs program will address the need to develop and test influenza vaccines that protect against new and emerging strains, and ultimately prevent more disease,” said Dr. Neuzil.
Under Dr. Neuzil’s leadership, CVD has assembled an expert and accomplished team with extensive clinical research experience as well as virology, immunology, and influenza expertise. The research includes clinical trials and challenge studies in adults as well as in special populations, such as children, pregnant women, and the elderly.
Throughout her career, Dr. Neuzil has conducted clinical and epidemiologic studies on vaccine-preventable diseases, yielding high profile publications that inform policy decision and public health actions. At the global non-profit PATH enterprise, Dr. Neuzil was instrumental in the global introduction of vaccines against rotavirus, HPV and Japanese encephalitis. At CVD, she leads a large international, consortium funded by the Bill and Melinda Gates Foundation to accelerate the introduction of a typhoid vaccines into low resource settings worldwide. In addition, Dr. Neuzil has a robust influenza research program. She is dedicated to training and directs a n NIAID T32 Training Grant in Vaccinology, where she mentors and supports scientists around the globe.
Dr. Neuzil’s research capabilities are complemented by nearly 20 years of involvement in domestic and international policy, including membership on the CDC Advisory Committee on Immunization Practices (ACIP). She currently serves as the only U.S. member of the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization (SAGE). In addition, Dr. Neuzil has contributed more than 200 scientific publications on vaccines and infectious diseases.
“This contract brings together a broad cross-section of researchers at UMSOM, who are experts in virology, vaccinology, and immunology. For decades, CVD has been a leader in researching and developing interventions for the most challenging diseases that impact the world’s most vulnerable populations. With this generous funding, and Dr. Neuzil’s expertise and leadership, CVD will be able to make pathbreaking discoveries, and test new vaccines against this persistent infection that affects millions of people around the world,” said UMSOM’s Dean Reece, who is also the Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor.
The CIVICs program was jointly developed by NIAID’s Division of Allergy, Immunology and Transplantation and the Division of Microbiology and Infectious Diseases to advance development and clinical testing of improved seasonal and universal influenza vaccines that provide durable, broadly cross-protective immunity.
“This contract will unite the greatest scientific minds in our state and nation toward a mission to improve our national public health,” said U.S. Senator Ben Cardin (D-Md). “Both the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health and the National Institute of Allergy and Infectious Disease have made incredible contributions to critical and lifesaving developments in disease prevention and treatment. Influenza is a common, yet complex illness that continues to put our most vulnerable citizens at risk. Through this public-private partnership, researchers will be able to clear the path for advancements in vaccination to better prepare our society for 21st century health needs. I’m proud that it will take place right here in the great state of Maryland.”
The CVD CIVIC program builds upon decades of clinical vaccine research at the CVD, much of which is contracted through the NIAID’s-supported Vaccine and Treatment Evaluation Unit (VTEU) network. CVD, as a part of the VTEU network, is conducting vaccine trials against influenza and other diseases. In addition, CVD is studying vaccines to protect against malaria, anthrax, Dengue, Ebola virus, meningitis, and Hantaan virus. This project has been funded in whole or in part with Federal funds from the NIAID, NIH, and Department of Health and Human Services, under Contract No. 75N93019C00055.
News Conference Image Gallery
.jpg)
.jpg)
About the University of Maryland School of Medicine
Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and more than $540 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact more than $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th highest among public medical schools in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu
Contact
Department of Anesthesiology
(410) 328-6120 (phone)
(410) 328-5531 (fax)
newsletter@som.umaryland.edu
Joanne Morrison
Director of Marketing and Public Relations
Center for Vaccine Development and Global Health
University of Maryland School of Medicine
jmorrison@som.umaryland.edu
Office: (410) 706-2884
Mobile: (202) 841-3369
Related stories
Thursday, March 28, 2024
NIH selects Dr. Kathleen Neuzil as Director of The Fogarty International Center
Kathleen M. Neuzil, MD, MPH, Director of the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health, has been named the 13th director of the Fogarty International Center (FIC), which is part of the National Institutes of Health (NIH). Dr. Neuzil will be the first woman to hold the permanent directorship since the center’s founding in 1968 and will also hold the position of Associate Director for International Research at NIH.
Tuesday, December 20, 2022
COVID Vaccines Prevented 3 Million Deaths in the U.S., New Analysis Finds
In the two years since the first COVID-19 vaccines were given to patients in the U.S., the vaccines had the cumulative effect of preventing 18 million hospitalizations and 3 million deaths. That is based on a new modeling analysis conducted by a researcher at the University of Maryland School of Medicine (UMSOM) and her colleagues. Results of the analysis were published by the Commonwealth Fund.
Friday, February 05, 2021
UM School of Medicine Researchers Demonstrate Strong Immune Response for New COVID-19 Vaccine in Pre-Clinical Tests
Researchers at the University of Maryland School of Medicine (UMSOM) have found promising results in pre-clinical studies for a new experimental vaccine against COVID-19 made by Novavax. The vaccine was found to generate a robust immune response in animals exposed to the vaccine with strong data indicating safety and efficacy, according to the study published recently in the journal Nature Communications. The results have been used to begin testing the vaccine in human trials in the U.S. with a Phase 3 trial that recently launched at the UMSOM’s Center for Vaccine Development and Global Health.
Thursday, July 02, 2020
UMSOM Researchers Help Weigh Role of Human Challenge Studies for COVID-19 Vaccine Development
Members of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, which includes Kathleen Neuzil, MD, MPH, DTPH, the Myron M. Levine, MD, DTPH Professor in Vaccinology and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), assessed the practical considerations and prerequisites for using controlled human infection models (CHIMs) to support development of a SARS-CoV-2 Vaccine.
Tuesday, December 10, 2019
UMSOM Researchers to Test Vaccine Designed to Protect Against Serious Illness from Contaminated Food and Water
Each year, millions of people contract serious diarrheal illnesses typically from contaminated food and water. Among the biggest causes of diarrheal diseases are the bacteria Shigella and enterotoxigenic Escherichia coli (ETEC), and researchers at the University of Maryland School of Medicine are testing a vaccine designed to offer protection against these serious pathogens.
Monday, August 19, 2019
UM School of Medicine Researcher Warns of Need for Malaria Drug to Treat Severe Cases in U.S.
Each year there are more than 200 million cases of malaria worldwide, a mosquito-borne disease caused by a parasite that brings on fever and body aches and, in some cases, more serious conditions such as coma and death. While the vast majority of these cases occur in sub-Saharan Africa and South Asia, the U.S. each year sees more than 1,500 cases, and currently there is limited access to an intravenously-administered (IV) drug needed for the more serious cases, according to a top malaria researcher at the University of Maryland School Medicine (UMSOM).
Tuesday, August 13, 2019
UM School of Medicine Researchers Begin Phase 1 Clinical Trial of Vaccine Against Mosquito-Borne Diseases
Mosquito-borne diseases including malaria, dengue and yellow fever, have a severe impact resulting in millions of deaths worldwide, hitting the world’s most vulnerable populations the hardest. Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental vaccine that is designed to protect against a series of these diseases.
Friday, March 08, 2019
UMSOM Researchers Unveil Progress and Challenges in Introducing Typhoid Conjugate Vaccine in Sub-Saharan Africa and Asia
Each year there are nearly 11 million cases of typhoid, a disease that is spread through contaminated food, drink and water. Researchers at the University of Maryland School of Medicine are leading an international consortium that is studying the impact of a typhoid conjugate vaccine (TCV) in an effort to accelerate introduction of the vaccine in countries in sub-Saharan Africa and Asia where there is a high burden of typhoid.
Monday, December 03, 2018
UMSOM and Groupe De Recherche Action En Sante Begin Second Typhoid Conjugate Vaccine Study in Africa
A new study has been launched in Burkina Faso for Bharat Biotech’s typhoid conjugate vaccine (TCV). It is the second clinical study underway in Africa for the vaccine and the first in West Africa. The vaccine study is a joint effort by the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine, (UMSOM) and Groupe de Recherche Action en Santé (GRAS) in Burkina Faso.
Friday, November 02, 2018
UMSOM Global Health Expert Named to Prestigious World Health Organization Immunization Panel
Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been named to the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization.
Wednesday, June 06, 2018
UMSOM Researchers Find that Silent Carriers of Malaria are Unlikely to Develop the Disease
In regions where malaria illness is widespread, it is common to find many individuals who are infected with malaria parasites (Plasmodium falciparum), but without symptoms. New research conducted by the University of Maryland School of Medicine (UMSOM) shows that treating these silent malaria cases could help stop the spread of malaria to others.
Tuesday, May 15, 2018
Tackling Malaria Transmission in Sub-Saharan Africa
Two malaria experts in the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine wrote a commentary published in the June Issue of The Lancet Global Health discussing the prevalence of malaria in school-age children in sub-Saharan Africa. Miriam Laufer, MD, Associate Professor of Pediatrics and Associate Director for Malaria Research CVD, and Lauren Cohee, MD, Instructor, Pediatrics, noted that often malaria infection is more common in school-age children than younger children and adults.
Monday, April 23, 2018
UM School of Medicine Launches Newly Organized Center for Vaccine Development and Global Health Under Leadership of International Vaccine Expert Dr. Kathleen Neuzil
University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a newly organized Center for Vaccine Development and Global Health (CVD). The new Center will be led by UMSOM Professor of Medicine and Pediatrics, Kathleen Neuzil, MD MPH, FIDSA, one of the world’s most influential research scientists and advocates in vaccine development and policy.
Thursday, September 28, 2017
UM SOM Vaccine Expert Warns of Risks of Influenza to Older Populations
“Protect yourself and others by getting the flu shot” was the message from Kathleen Neuzil, MD, MPH, FIDSA, Director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM). Dr. Neuzil was among the speakers at a press conference hosted by the National Foundation for Infectious Diseases. U.S. Secretary of Health and Human Services, Thomas E Price, MD, also spoke at the press conference and urged people to get their flu shot. The panel members all received their flu shots following the press conference.
Monday, May 15, 2017
U.S. CDC Recommends Use of Cholera Vaccine Developed by University of Maryland School of Medicine
A cholera vaccine developed by scientists at the University of Maryland School of Medicine’s Center for Vaccine Development (CVD) has been recommended by the U.S. Centers for Disease Control and Prevention (CDC) for use as a protection for U.S. adults traveling to areas with cholera. The CDC’s latest recommendation was published on May 11, in Morbidity and Mortality Weekly Report.
Thursday, November 10, 2016
International Consortium Receives $36.9 Million Grant to Fight Typhoid
Typhoid fever, a bacterial infection that causes high fever and other disabling symptoms, remains a serious global problem in the developing world: it kills almost a quarter of a million people annually, and infects about 21 million.
Thursday, September 22, 2016
University of Maryland School of Medicine Holds Inaugural Global Health Summit
The Institute for Global Health (IGH) at the University of Maryland School of Medicine (UM SOM) will hold its first Global Health Summit on September 26. The event, which will take place from noon to 6 p.m. in the SMC Campus Center at 621 W. Lombard Street, will seek to foster collaboration among scientists and promote new and innovative global health research at UM SOM, as well as at other schools at the University of Maryland, Baltimore (UMB). Faculty and staff from UM SOM, as well as other schools are welcome at the event.
Thursday, August 04, 2016
UM SOM is Center Stage in Testing National Institutes of Health Zika Vaccine
UM SOM'S Center for Vaccine Development, tapped previously for Ebola vaccine, now steps up to help develop first Zika vaccine.
Wednesday, June 29, 2016
UM SOM Researchers Awarded Grant to Use Innovative Alternative to Autopsies to Better Understand Child Mortality
Kathleen Neuzil, MD, MPH, director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM), and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that CVD has been awarded a large grant from the Bill & Melinda Gates Foundation for research that will help determine why so many children under five are dying in the world’s poorest countries. The grant will fund use of an innovative alternative to traditional autopsy known as minimally invasive tissue sampling. The technique, which involves the collection of tissue samples with fine needles, allows researchers to quickly identify the cause of death, and help illuminate ways to save lives and improve the health of children in these vulnerable areas.
Tuesday, April 12, 2016
UM SOM Researcher Dr. Kathleen Neuzil Honored by Vanderbilt University School of Medicine
The Vanderbilt University School of Medicine (VUSM) has announced that Kathleen Neuzil, MD, MPH, director of the Center for Vaccine Development at the University of Maryland School of Medicine (UM SOM), has received the 2016 Vanderbilt University School of Medicine Distinguished Alumni Award.